{'fraction_non_alphanumeric': 0.02077562326869806, 'fraction_numerical': 0.004155124653739612, 'mean_word_length': 4.922131147540983, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Estimation of the serum level of a proliferation-inducing ligand in patients with psoriasis and lichen planus

Background A proliferation-inducing ligand (APRIL) is a new member of the tumor-necrosis factor superfamily. Elevated serum APRIL level has been found in some autoimmune diseases. APRIL costimulates B cells in vitro and in vivo. In addition, APRIL also has an important role in T-cell activation and survival. Objective The aim of the present study was to determine the serum level of APRIL in patients with psoriasis and lichen planus (LP) to evaluate its role in the pathogenesis of both diseases. Patients and methods This study included 40 patients with psoriasis (group II), 40 patients with LP (group III), and 20 healthy individuals who served as controls (group I). Serum samples were taken from all patients and controls for the detection of serum APRIL level by using the enzyme-linked immunosorbent assay. Results A significant increase was found in the mean serum APRIL level in patients with psoriasis and LP when compared with controls. Serum APRIL level was significantly correlated with severity of psoriasis, as determined by the psoriasis area and severity index score. Conclusion APRIL could be implicated as an important cytokine in the pathogenesis of psoriasis and LP. APRIL could be used as a useful marker for assessing psoriasis severity and open the way for further therapeutic approaches for both diseases.